The latter group is composed of monoclonal antibodies, such as benralizumab (anti-IL-5), dupilumab (anti-IL-4), mepolizumab (anti-IL-5), omalizumab (anti-IgE), and reslizumab (anti-IL-5), which are approved for the treatment of severe asthma [8]. This evidence concerns the gene IL4 and asthma.